ClinicalTrials.gg
Not yet recruitingNCT07485764Updated Mar 25, 2026

Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients

A Phase 4 interventional study of Secukinumab 300mg s.c. and Metformin in Psoriasis, Plaque Psoriasis and Moderate-to-severe Plaque Psoriasis, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Planned enrollment
86th of 182
186 · median 171
Started
2026
with 17 others
Phase 4
12 of 206
3 open now
Primary completion
2026-06
later than 21 of 65 live
Registered
186th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 86th largest by planned enrollment of the 182 interventional ones that give a count, is one of 18 that started in 2026, is one of 12 in phase 4, reaches primary completion later than 21 of the 65 other live ones, and was the 186th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, multicenter clinical trial conducted in China. The study aims to evaluate the efficacy and safety of metformin combined with secukinumab in the treatment of moderate-to-severe plaque psoriasis in overweight or obese Chinese patients.

A total of approximately 186 participants will be enrolled and randomly assigned in a 1:1 ratio to receive either secukinumab plus metformin or secukinumab plus placebo. The study consists of a screening period, an induction period, a maintenance period, and a follow-up period, with a total duration of 60 weeks.

The primary endpoints are the proportions of participants achieving PASI75 (≥75% improvement in Psoriasis Area and Severity Index) and an IGA score of 0 or 1 (clear or almost clear) at Week 24. Secondary endpoints include PASI90, quality of life (DLQI), pruritus NRS score, metabolic parameters, and safety assessments.

This study aims to provide a more effective combination therapy for psoriasis patients with overweight or obesity.

03

Conditions studied

  • Psoriasis
  • Plaque Psoriasis
  • Moderate-to-severe Plaque Psoriasis
  • Overweight , Obesity

Keywords

  • Metformin
  • Secukinumab
  • IL-17 Inhibitor
  • Randomized Controlled Trial
  • Double-Blind
  • Placebo-Controlled
  • Chinese Patients
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects voluntarily participate in the study and sign the form.
  2. Aged 18-75 years (inclusive) at the time of signing informed consent, male or female.
  3. Diagnosed with chronic plaque psoriasis for >=6 months prior to the first study drug administration.
  4. Overweight/obesity: (BMI) >=25 kg/m².
  5. Moderate-to-severe plaque psoriasis (defined as):

    Psoriasis Area and Severity Index (PASI) score >=12 at screening and prior to first dose.

    Investigator's Global Assessment (IGA) score >=3 at screening and prior to first dose.

    Stable disease within 2 months prior to randomization.

  6. Deemed candidates for phototherapy or systemic therapy by the investigator, defined as subjects with moderate-to-severe chronic plaque psoriasis uncontrolled by:

    Topical therapy and/or phototherapy and/or prior systemic therapy.

  7. Women of must have a negative pregnancy test at screening and prior to the first dose of study medication (Day 0). Both women of childbearing potential and male patients with reproductive capacity must agree to use highly effective methods during the study and for 15 weeks following the last dose.
  8. Lactating women agree to discontinue breastfeeding during the study and for 15 weeks following the last dose of study medication.
  9. Subjects must be capable of effective communication with investigators and adhere to the clinical trial protocol to complete all study requirements. -

Exclusion criteria

Exclusion Criteria:

  • 1: \<25 kg/m². 2: Presence of guttate, pustular, or erythrodermic psoriasis, or other diseases that may confound treatment outcomes (e.g., cutaneous lesions, systemic diseases).

    3: Drug-induced psoriasis (e.g., new-onset or exacerbated psoriasis caused by beta-blockers, calcium channel blockers, or lithium).

    4: Use of prohibited medications: Systemic non-biologic agents (e.g., , leflunomide, methotrexate, cyclosporine, retinoids, azathioprine, mycophenolate mofetil, traditional Chinese medicines for psoriasis) within 4 weeks prior to screening.

Etanercept or its biosimilars within 4 weeks prior to screening; TNF-α inhibitors or their biosimilars within 12 weeks prior to screening.

Other biologic agents for psoriasis (e.g., IL-12/23 or IL-23 inhibitors) within 5 half-lives of the drug prior to screening.

5: Prior use of secukinumab or other IL-17A/IL-17R-targeted biologic agents within 12 weeks prior to screening.

6: History of within the past 5 years (e.g., cutaneous squamous cell carcinoma, basal cell carcinoma, cervical carcinoma in situ).

7: Active inflammatory diseases other than psoriasis that may confound the evaluation of secukinumab efficacy.

8: Metabolic or inflammatory diseases (e.g., type 2 diabetes) that may confound the evaluation of metformin efficacy.

9: History of lymphoproliferative disorders (e.g., lymphoma, lymphadenopathy) or splenomegaly.

10: Opportunistic infections within 6 months prior to screening (e.g., herpes zoster, CMV, Mycoplasma, Pneumocystis jirovecii, histoplasmosis, candidiasis, aspergillosis, NTM).

11: Chronic or recurrent infectious diseases (e.g., chronic hepatitis, pyelonephritis) or severe/life-threatening infections within 6 months prior to screening; current signs/symptoms suggestive of infection (e.g., fever, cough, dysuria, abdominal pain, diarrhea, infected skin wounds).

12: High risk of infection (e.g., leg ulcers, indwelling urinary catheters, recurrent chest infections, bedridden/wheelchair-bound status).

13: Major surgery within 8 weeks prior to screening or planned during the study, deemed to pose unacceptable risk by the investigator.

14: Live virus/bacterial vaccines (e.g., BCG) within 6 weeks prior to screening or planned during the study/within 15 weeks after last dose.

15: Participation in another clinical trial within 4 weeks prior to screening or within 5 half-lives of the product (whichever is longer).

16: Laboratory abnormalities: \<8.5 g/dL WBC \<2,500/μL ANC \<1,500/μL \<100,000/μL /AST >2× Creatinine >176.8 μmol/L (2.0 mg/dL) 17: Active (positive HBsAg). 18: Positive antibody. 19: infection or positive HIV antibody. 20: Syphilis infection. 21: Active or latent tuberculosis at screening. 22: to trial drug , murine/human proteins, or immunoglobulin products.

23: Inability to communicate/comply (e.g., psychiatric disorders, frequent travel, lack of motivation).

24: Other conditions deemed by the investigator to compromise study participation.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
186 participants (estimated)

Study arms

  • Experimental
    Metformin + Secukinumab

    Participants receive secukinumab (300 mg subcutaneous injection at Weeks 0, 1, 2, 3, 4, then every 4 weeks thereafter) plus metformin (oral, starting at 500 mg/day, titrated weekly to a maximum of 2000 mg/day as tolerated, then maintained)

    Drug: Secukinumab 300mg s.c. · Drug: Metformin

  • Placebo comparator
    Placebo + Secukinumab

    Participants receive secukinumab (same dosing regimen as the experimental group) plus placebo tablets (identical in appearance to metformin, administered orally following the same titration schedule).

    Drug: Secukinumab 300mg s.c. · Drug: Placebo

Interventions

  • DrugSecukinumabStudies of SecukinumabSecukinumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Secukinumab is a fully human monoclonal antibody that selectively targets interleukin-17A (IL-17A), a key cytokine involved in the pathogenesis of psoriasis. In this study, secukinumab is administered as a subcutaneous injection at a dose of 300 mg. The dosing schedule includes weekly injections during the induction period (Weeks 0, 1, 2, 3, and 4), followed by maintenance dosing every 4 weeks thereafter. It is used in both the experimental and control arms.

  • Oral biguanide medication. Starting dose: 500 mg/day, titrated weekly by 500 mg to a maximum of 2000 mg/day (or maximum tolerated dose, e.g., 1500 mg/day), then maintained.

  • DrugPlacebo

    Placebo tablets matching metformin in appearance, administered orally following the same titration schedule.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving PASI75 at Week 24

    Percentage of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI) score from baseline to Week 24.

    Time frame: Baseline to Week 24

  2. Proportion of Participants Achieving IGA Score of 0 or 1 at Week 24

    Percentage of participants achieving an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) at Week 24.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Proportion of Participants Achieving PASI90 at Week 24

    Percentage of participants achieving at least 90% improvement in PASI score from baseline to Week 24

    Time frame: Baseline to Week 24

  2. Proportion of Participants Achieving PASI75/90/100 at Week 52

    Percentage of participants achieving PASI75, PASI90, or PASI100 at Week 52.

    Time frame: Baseline to Week 52

  3. Proportion of Participants Achieving IGA 0/1 at Week 52

    Percentage of participants achieving IGA score of 0 or 1 at Week 52.

    Time frame: Baseline to Week 52

  4. Change in DLQI Score at Week 24

    Mean change in Dermatology Life Quality Index (DLQI) score from baseline to Week 24.The DLQI is a 10-item questionnaire with scores ranging from 0 (no impairment) to 30 (maximum impairment), where higher scores indicate worse quality of life and greater disease burden.

    Time frame: Baseline to Week 24

  5. Proportion of Participants with DLQI Score of 0 or 1 at Week 24

    Percentage of participants achieving a DLQI score of 0 or 1 (no impact on quality of life) at Week 24.

    Time frame: Baseline to Week 24

  6. Change in Pruritus NRS Score at Week 24

    Mean change in pruritus Numerical Rating Scale (NRS) score from baseline to Week 24.The pruritus NRS is a 11-point scale with scores ranging from 0 (no itch) to 10 (worst imaginable itch), where higher scores indicate more severe pruritus.

    Time frame: Baseline to Week 24

  7. Proportion of Participants with ≥2.5% Weight Loss at Week 24

    Percentage of participants achieving at least 2.5% reduction in body weight from baseline to Week 24.

    Time frame: Baseline to Week 24

  8. Proportion of Participants Achieving PASI75/90/100 at Week 52 Among Those Who Achieved PASI50 but Not PASI75 at Week 24

    Among participants who achieved at least 50% improvement in PASI score (PASI50) but did not achieve 75% improvement (PASI75) at Week 24, the percentage who subsequently achieve PASI75, PASI90, or PASI100 at Week 52.

    Time frame: Week 24 to Week 52

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2026, 0 months later.

Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 0 months is below that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 20, 2026
StartEst.
Jun 2026
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2029
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07485764
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Jun 2029 (estimated)
Last update
Mar 25, 2026

Study contacts

Jing Yang, MD
Contact
fly_y1@163.com
+86 181 7133 9758
Juan Tao, MD
principal investigator · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion